Circulating tumor DNA as markers of dynamic recurrence risk and adjuvant chemotherapy benefit in resected non-small cell lung cancer.
Wei Guo(Chinese Academy of Medical Sciences & Peking Union Medical College), Shugeng Gao(Chinese Academy of Medical Sciences & Peking Union Medical College), Yang Xu(Genesee Community College), Yue Peng(Chinese Academy of Medical Sciences & Peking Union Medical College), Bin Qiu(Shandong Academy of Agricultural Sciences), Fengwei Tan(Chinese Academy of Medical Sciences & Peking Union Medical College), Ying Ji(Regions Hospital), Hua Bao, Fan Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Qi Xue(Chinese Academy of Medical Sciences & Peking Union Medical College), Yang Shao(Sanya University), Xiaoxi Chen(Soochow University), Fang Lv(Liaoning Normal University)
Cited by 2
Related Papers
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2023|1k
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
|Journal of Thoracic Oncology|2020|415
Impact of Examined Lymph Node Count on Precise Staging and Long-Term Survival of Resected Non–Small-Cell Lung Cancer: A Population Study of the US SEER Database and a Chinese Multi-Institutional Registry
|Journal of Clinical Oncology|2017|358
METTL3 promotes tumour development by decreasing APC expression mediated by APC mRNA N6-methyladenosine-dependent YTHDF binding
|Nature Communications|2021|193
Mouse Embryonic Head as a Site for Hematopoietic Stem Cell Development
|Cell stem cell|2012|192